IDH2 and acute myeloid leukemia: Thus, as supported by preclinical studies, a phase Ib study was proposed based on the administration of Enasidenib and MEK inhibitor Cobimetinib in R/R AML patients who have co-occurring IDH2 and RAS signaling mutations [59].